Genoox, a genetic data analysis company, recently partnered with Bionano Genomics to better identify the nearly 20k potentially disease-causing SVs in the human genome. By combining Genoox technology and Bionano mapping data, the new Genoox integrated platform will offer clinicians a single platform for accurate detection of genetic mutations for rare disease. Genoox and Bionano intend to co-sell and co-market the integrated platform for research and future clinical applications.Children’s
Read More
Genomic Analysis Startup Genoox Raises $6M to Expand in the US Market
Genoox, the genomic analysis company making it easier for doctors, clinicians, and researchers to analyze and act on genetic sequencing data has raised $6 million in funding led by Inimiti Capital Partners and Glilot Capital Partners. With this investment, Genoox will also be expanding their genomic services into the U.S. healthcare market, providing medical facilities with innovative solutions to help solve real and pressing healthcare problems. Genoox has an international footprint, with a
Read More
Penn Medicine’s Abramson Cancer Center Launches Initiative to Improve & Personalize BRCA Mutations
Cancer experts at the Basser Center for BRCA in the Abramson Cancer Center of the University of Pennsylvania have announced a new collaboration with Tempus to improve and personalize treatment for patients with heritable BRCA mutations. Tempus, a technology company focused on helping doctors personalize cancer treatment will analyze the molecular and clinical data of patients who were treated at the Basser Center and harbor a BRCA mutation using machine learning and advanced
Read More
IBM Watson, Quest Diagnostics Partner to Offer Gene Sequencing Service
IBM Watson is teaming up with Quest Diagnostics to launch Watson Genomics from Quest Diagnostics, a gene sequencing and Watson diagnostic analysis service to help oncologists deliver precision medicine to their patients. Together with Memorial Sloan Kettering Cancer Center (MSK), the service will provide a personalized tumor analysis of a patient’s sequenced genomic tumor that is supported by clinical evidence. As part of the precision medicine partnership, The Broad Institute of MIT and Harvard
Read More
FDA Unveils Open Source Platform for Genomic Sequencing Data
On Wednesday, the FDA announced the launch of an open source platform for community sharing of genomic sequencing data called precisionFDA. DNAnexus, the provider of cloud-based genome informatics and data management was awarded a research and development contract by the FDA to build the platform. precisionFDA is the FDA's answer to its role under the White House’s Precision Medicine Initiative is to review the current regulatory landscape and develop a streamlined approach to evaluating
Read More